This dual-axis mechanism provides a comprehensive understanding of how PLS3 drives HNSCC progression and demonstrates its value as a therapeutic target for both anti-tumor as well as immune-modulatory strategies. The gene discussed is PLS3; the disease is head and neck squamous cell carcinoma.